Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer

By sjmartinez • August 14, 2023

Pegram M, Pietras R, Dang CT, Murthy R, Bachelot T, Janni W, Sharma P, Hamilton E, Saura C. Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer. Ther Adv Med Oncol. 2023 Aug 11;15:17588359231187201. doi: 10.1177/17588359231187201. PMID: 37576607; PMCID: PMC10422890.

Tags: CDK4/6 inhibitors, Hematology/Oncology, HR+/HER2+ breast cancer, metastatic breast cancer, Publications, resistance, triple-positive breast cancer

PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers

Gu Y, Ly A, Rodriguez S, Zhang H, Kim J, Mao Z, Sachdeva A, Zomorodian N, Pellegrini M, Li G, Liu S, Drakaki A, Rettig[...]

Alcohol and cannabis use associated with cardiometabolic biomarkers among “All of Us” cancer survivors

Arizpe A, Chapman TM, Rodriguez C, Carvajal A, Queen KJ, Navarro S, Ochoa-Dominguez CY, Kim SE, Toledo-Corral CM, Farias AJ. Alcohol and cannabis use associated[...]

Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease

Benitez CM, Sahlstedt H, Sonni I, Brynolfsson J, Berenji GR, Juarez JE, Kane N, Tsai S, Rettig M, Nickols NG, Duriseti S. Treatment Response Assessment[...]